Proximity to Brainstem at Recurrence is Associated with Decreased Survival in IDH Wild-Type Glioblastoma

被引：0
|
作者：
Bajaj, A. [1 ]
Benishay, E. T. [1 ]
Helenowski, I. B. [2 ]
Savoor, R. [1 ]
Drumm, M. R. [3 ]
Rammohan, N. [4 ]
Sachdev, S. [5 ]
Horbinski, C. M. [6 ]
Kruser, T. [5 ]
机构：
[1] Northwestern Univ, Dept Radiat Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Northwestern Univ, Dept Prevent Med, Div Biostat, Chicago, IL 60611 USA
[3] Northwestern Univ, Dept Neurol Surg, Chicago, IL 60611 USA
[4] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Northwestern Univ, Dept Radiat Oncol, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA
[6] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3235
引用
收藏
页码：E587 / E587
页数：1
相关论文
共 50 条
  • [31] Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors
    Hagiwara, Akifumi
    Oughourlian, Talia C.
    Cho, Nicholas S.
    Schlossman, Jacob
    Wang, Chencai
    Yao, Jingwen
    Raymond, Catalina
    Everson, Richard
    Patel, Kunal
    Mareninov, Sergey
    Rodriguez, Fausto J.
    Salamon, Noriko
    Pope, Whitney B.
    Nghiemphu, Phioanh L.
    Liau, Linda M.
    Prins, Robert M.
    Cloughesy, Timothy F.
    Ellingson, Benjamin M.
    NEURO-ONCOLOGY, 2022, 24 (06) : 1020 - 1028
  • [32] LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients
    Mock, Andreas
    Geisenberger, Christoph
    Orlik, Christian
    Warta, Rolf
    Schwager, Christian
    Jungk, Christine
    Dutruel, Celine
    Geiselhart, Lea
    Weichenhan, Dieter
    Zucknick, Manuela
    Nied, Ann-Katrin
    Friauf, Sara
    Exner, Janina
    Capper, David
    Hartmann, Christian
    Lahrmann, Bernd
    Grabe, Niels
    Debus, Juergen
    von Deimling, Andreas
    Popanda, Odilia
    Plass, Christoph
    Unterberg, Andreas
    Abdollahi, Amir
    Schmezer, Peter
    Herold-Mende, Christel
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (02) : 424 - 432
  • [33] MRI Atlas of IDH Wild-Type Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes
    Roux, Alexandre
    Roca, Pauline
    Edjlali, Myriam
    Sato, Kanako
    Zanello, Marc
    Dezamis, Edouard
    Gori, Pietro
    Lion, Stephanie
    Fleury, Ariane
    Dhermain, Frederic
    Meder, Jean-Francois
    Chretien, Fabrice
    Lechapt, Emmanuele
    Varlet, Pascale
    Oppenheim, Catherine
    Pallud, Johan
    RADIOLOGY, 2019, 293 (03) : 633 - 643
  • [34] Validation of the prognostic value of 9-gene ATE score for IDH wild-type glioblastoma
    Wang, Zihao
    Gao, Lu
    Wang, Yaning
    Chang, Mengqi
    Xing, Hao
    Wang, Yu
    Xing, Bing
    Ma, Wenbin
    NEURO-ONCOLOGY, 2021, 23 (07) : 1197 - 1199
  • [35] Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma
    Nam, Yoonhee
    Koo, Harim
    Yang, Yingxi
    Shin, Sang
    Zhu, Zhihan
    Kim, Donggeon
    Cho, Hee Jin
    Mu, Quanhua
    Choi, Seung Won
    Sa, Jason K.
    Seo, Yun Jee
    Kim, Yejin
    Lee, Kyoungmin
    Oh, Jeong-Woo
    Kwon, Yong-Jun
    Park, Woong-Yang
    Kong, Doo-Sik
    Seol, Ho Jun
    Lee, Jung-Il
    Park, Chul-Kee
    Lee, Hye Won
    Yoon, Yeup
    Wang, Jiguang
    GENOME MEDICINE, 2023, 15 (01)
  • [36] Association of MGMT Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type IDH Glioblastoma
    Kim, Moonsik
    Yoo, Jihwan
    Chang, Jong Hee
    Kim, Se Hoon
    ANTICANCER RESEARCH, 2022, 42 (01) : 335 - 341
  • [37] MOLECULAR PROFILE CONSENSUS CLUSTERING DEFINES CLINICALLY DISTINCT GROUPS IN IDH WILD-TYPE GLIOBLASTOMA
    Gersey, Zachary
    Mallela, Arka
    Zhang, Xiaoran
    Pease, Matthew
    Abdelhakiem, Mohamed
    Pearce, Thomas
    Lieberman, Frank
    Mantica, Megan
    Phillips, Richard
    Bagley, Stephen
    Nasrallah, MacLean
    Binder, Zev
    Brem, Steven
    Chen, Isaac
    O'Rourke, Donald M.
    Zinn, Pascal
    Siddiqui, Zaid
    Amankulor, Nduka
    NEURO-ONCOLOGY, 2022, 24 : 260 - 261
  • [38] Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma
    Yoonhee Nam
    Harim Koo
    Yingxi Yang
    Sang Shin
    Zhihan Zhu
    Donggeon Kim
    Hee Jin Cho
    Quanhua Mu
    Seung Won Choi
    Jason K. Sa
    Yun Jee Seo
    Yejin Kim
    Kyoungmin Lee
    Jeong-Woo Oh
    Yong-Jun Kwon
    Woong-Yang Park
    Doo-Sik Kong
    Ho Jun Seol
    Jung-Il Lee
    Chul-Kee Park
    Hye Won Lee
    Yeup Yoon
    Jiguang Wang
    Genome Medicine, 15
  • [39] IDH Wild-type Glioblastoma Presenting with Seizure: Clinical Specificity, and Oncologic and Surgical Outcomes.
    Pesce, Alessandro
    Armocida, Daniele
    Paglia, Francesco
    Palmieri, Mauro
    Frati, Alessandro
    D'Andrea, Giancarlo
    Salvati, Maurizio
    Santoro, Antonio
    JOURNAL OF NEUROLOGICAL SURGERY PART A-CENTRAL EUROPEAN NEUROSURGERY, 2022, 83 (04) : 351 - 360
  • [40] A Case of Long-Term Survival After Glioblastoma, IDH-Wild Type
    Webb, Lauren M.
    Neth, Bryan J.
    Raghunathan, Aditya
    Greipp, Patricia T.
    Ida, Cristiane M.
    Carabenciov, Ivan D.
    Ruff, Michael W.
    NEUROLOGIST, 2024, 29 (04) : 254 - 258
12345